...
首页> 外文期刊>Breastfeeding medicine: the official journal of the Academy of Breastfeeding Medicine >Family history of breast cancer predicts Breastmilk protein expression
【24h】

Family history of breast cancer predicts Breastmilk protein expression

机译:乳腺癌家族史预测母乳蛋白表达

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: In the past decade, targeted therapy with antiangiogenic drugs has become standard of care for most types of metastatic, progressive thyroid cancer. While these drugs were thought initially to be less toxic than traditional chemotherapy, they can have rare but serious and fatal toxicities. Once such toxicity that has been reported in other tumor types is upper airway fistula formation, which can be life-threatening. Summary: Here, we describe three patients treated with antiangiogenic tyrosine kinase inhibitors at two academic institutions who developed aerodigestive fistula. All three patients had risk factors for fistula formation, which included external beam radiation and/or large tumor with invasion of the tracheal wall. Conclusions: Fistula formation is a known but rare side effect of antiangiogenic tyrosine kinase inhibitors. Knowledge of the risk factors that may predispose thyroid cancer patients to this serious adverse event is vital prior to prescribing antiangiogenics. Particular caution should be observed when using these drugs in patients undergoing radiation therapy or surgery, or in patients whose tumor is invading vital structures of the neck, as they may be at higher risk of developing this rare complication. In these patients, antiangiogenic tyrosine kinase inhibitors should be used cautiously, patients should be aware of the risk, and physicians should monitor patients for symptoms of fistula.
机译:背景:在过去的十年中,抗血管生成药物的靶向治疗已成为大多数类型的转移性进行性甲状腺癌的治疗标准。尽管最初认为这些药物的毒性不如传统化学疗法,但它们可能具有罕见但严重且致命的毒性。曾经在其他肿瘤类型中报告过这种毒性的是上呼吸道瘘管形成,这可能危及生命。摘要:在这里,我们描述了在两家学术机构中出现航空消化道瘘的三例接受抗血管生成酪氨酸激酶抑制剂治疗的患者。三名患者均具有瘘管形成的危险因素,包括外部束辐射和/或伴有气管壁浸润的大肿瘤。结论:瘘管形成是抗血管生成酪氨酸激酶抑制剂的已知但罕见的副作用。在开具抗血管生成药物之前,了解可能使甲状腺癌患者容易发生这种严重不良事件的危险因素至关重要。在正在接受放射治疗或手术的患者或肿瘤侵犯颈部重要结构的患者中使用这些药物时,应特别小心,因为它们可能更容易发生这种罕见的并发症。在这些患者中,应谨慎使用抗血管生成酪氨酸激酶抑制剂,患者应意识到其风险,医生应监测患者的瘘管症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号